Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Clin Rheumatol

Search In Journal Title:

Abbravation: Clinical Rheumatology

Search In Journal Abbravation:

Publisher

Springer-Verlag

Search In Publisher:

DOI

10.1007/bf02730498

Search In DOI:

ISSN

1434-9949

Search In ISSN:
Search In Title Of Papers:

Neridronate and human osteoblasts in normal osteo

Authors: Addolorata Corrado Francesco Paolo Cantatore Maria Grano Silvia Colucci
Publish Date: 2005/08/10
Volume: 24, Issue: 5, Pages: 527-534
PDF Link

Abstract

The objective of this study was to evaluate the metabolic in vitro effect of the bisphosphonate neridronate on normal and pathological human osteoblasts Primary human osteoblast cultures were obtained from cancellous bone of osteoarthritic OA and osteoporotic OP patients and a corresponding healthy control group Osteocalcin production was evaluated by cultured cells in neridronate 10−4 M and 10−6 M both under basal conditions and after vitamin D3 stimulation In the absence of neridronate vitamin D3 increased osteocalcin production in all cell cultures under the same conditions and in the absence of vitamin D3 OA osteoblasts showed a significantly higher osteocalcin production whereas OP osteoblasts showed a significantly lower osteocalcin production compared to the normal osteoblasts respectively In all cellular populations neridronate at a higher concentration 10−4 M induced a reduction in osteocalcin synthesis but in normal and osteoarthritic osteoblasts did not reduce the stimulatory effect of vitamin D3 whereas it inhibited the vitamin D3induced increase of osteocalcin synthesis in the osteoporotic cells In normal and osteoporotic osteoblasts stimulation with the lower neridronate concentration 10−6 M significantly increased osteocalcin production which was further enhanced by vitamin D3 as an additional effect of the combined treatment In OA osteoblasts neridronate 10−6 M did not induce an increase in osteocalcin synthesis and the additional effect of combined treatment with vitamin D3 was not observed Neridronate can modify the metabolic activity of human osteoblasts by enhancing or decreasing their biosynthetic activity both in normal and in pathological conditions depending on compound concentration and on different cell types These results confirm the validity of using neridronate at doses usually administered in treating osteoporosis and they suggest using it to treat other diseases which show an altered osteoblast metabolism such as osteoarthritis


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima–media in patients with systemic autoimmune diseases
  2. The virtuoso foot
  3. Responsiveness of the DASH score in surgically treated basal joint arthritis of the thumb: preliminary results
  4. RAPID3 scores and hand outcome measurements in RA patients: a preliminary study
  5. Bone mineral density in children with familial Mediterranean fever
  6. Chorea as a side effect of gabapentin (Neurontin®) in a patient with complex regional pain syndrome Type 1
  7. Risk factors in transient osteoporosis: a retrospective study on 23 cases
  8. Outcome of reactive arthritis after an extensive Finnish waterborne gastroenteritis outbreak: a 1-year prospective follow-up study
  9. Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement
  10. The autonomic nervous system in systemic sclerosis. A review
  11. Detection of anticardiolipin antibody IgG by time-resolved fluoroimmunoassay
  12. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan
  13. Rheumatoid arthritis: should we shift the focus from “Treat to Target” to “Treat to Work?”
  14. Intercellular adhesion molecules in systemic lupus erythematosus patients with lupus nephritis
  15. Severe deficiency of 25-hydroxyvitamin D 3 (25-OH-D 3 ) is associated with high disease activity of rheumatoid arthritis
  16. The expression of death decoy receptor 3 was increased in the patients with primary Sjögren’s syndrome
  17. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)
  18. Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared
  19. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge
  20. Group visits for rheumatoid arthritis patients: a pilot study
  21. Identification of transcription regulatory relationships in rheumatoid arthritis and osteoarthritis
  22. The impact of current health-related quality of life on future health outlook in patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome)
  23. Two cases demonstrating thalidomide’s efficacy in refractory lupus nephritis
  24. Rheumatoid arthritis among Nigerians: the first 200 patients from a rheumatology clinic
  25. The challenge of profound hypoglycorrhachia: two cases of sarcoidosis and review of the literature
  26. Chronic intestinal pseudo-obstruction in patients with systemic lupus erythematosus: report of four cases
  27. Relationship of Q angle and joint hypermobility and Q angle values in different positions
  28. Osteoarthritis of the hip or knee: which coexisting disorders are disabling?
  29. Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels
  30. T helper 1 type cytokines polymorphisms: association with susceptibility to Behçet’s disease
  31. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab
  32. Oxidative status in rheumatoid arthritis
  33. Impact and therapy of osteoarthritis: the Arthritis Care OA Nation 2012 survey
  34. Follicular bronchiolitis, an unusual cause of haemoptysis in giant cell arteritis
  35. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature
  36. Vitamin D and systemic lupus erythematosus: state of the art
  37. Challenges and opportunities for diagnosis and treatment of rheumatoid arthritis in Latin America
  38. Clostridium difficile : an under-recognized cause of reactive arthritis?
  39. Prevalence of rheumatic diseases in Raramuri people in Chihuahua, Mexico: a community-based study
  40. Clinical utility of magnetic resonance angiography (MRA) in the diagnosis and treatment of Takayasu’s arteritis
  41. A systematic review of homoeopathy for the treatment of fibromyalgia
  42. Do hip OA patients referred to orthopedic surgeons by general practitioners and rheumatologists differ?
  43. The pathway of estradiol-induced apoptosis in patients with systemic lupus erythematosus
  44. Antistreptococcal Response is Exaggerated in Children with Familial Mediterranean Fever
  45. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register
  46. Beware of the biologicals—hospitals may die: the Rheumatism Foundation Hospital, Heinola, Finland (1951–2010)
  47. Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate
  48. QT dispersion in uncomplicated familial Mediterranean fever
  49. Ultrasonographic evaluation of the muscle architecture in patients with systemic lupus erythematosus
  50. Changes in mononuclear cell function in patients with rheumatoid arthritis following treatment with auranofin
  51. Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis
  52. Autonomic dysfunction in psoriatic arthritis
  53. Exercise therapy for patients with diffuse idiopathic skeletal hyperostosis
  54. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients
  55. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis
  56. Increased expression of IL - 28RA mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
  57. Contrast-enhanced power Doppler sonography of knee synovitis in rheumatoid arthritis: assessment of therapeutic response
  58. Long-term follow-up of autologous stem cell transplantation for severe paediatric systemic lupus erythematosus
  59. Fibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome
  60. Evaluation of a mail-delivered, print-format, self-management program for persons with systemic sclerosis
  61. Serum galectin-3 level in systemic sclerosis
  62. Non-rheumatoid erosive arthritis associated with type I hereditary angioedema
  63. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases
  64. Familial Mediterranean fever responds well to infliximab: single case experience
  65. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases
  66. The role of PET/CT in Cogan’s syndrome
  67. Treatment of osteoporosis in renal insufficiency
  68. STAT4 rs7574865 G/T polymorphism is associated with rheumatoid arthritis and disease activity, but not with anti-CCP antibody levels in a Mexican population

Search Result: